Medivation, Inc. (MDVN) on Thursday announced publication of the results of its first Alzheimer's disease pivotal clinical trial of the investigational drug Dimebon in the July 19, 2008 issue of The Lancet.
Results showed that patients with mild-to-moderate Alzheimer's disease treated with Dimebon experienced statistically significant improvements compared to placebo in all the key aspects of the disease.
The benefit on the primary endpoint, the Alzheimer's Disease Assessment Scale-cognitive subscale at six months, was highly significant. Patients treated with Dimebon were also significantly improved at six months over baseline on all measures. Dimebon's benefit over placebo continued to increase throughout the 12-month treatment period.
For comments and feedback: editorial@rttnews.com